Otsuka’s medicine for PTSD with partner Lundbeck failed to win the backing of US regulatory advisers, a major setback in the drugmakers’ bid to bring the first new drug for the condition to market in more than two decades https://t.co/rR0B7sLNgG ...

Summary of Schrödinger (SDGR) 2025 Conference Call Company Overview - Schrödinger combines physics-based methods with artificial intelligence (AI) and machine learning to accelerate the discovery of novel chemical materials for life sciences and material sciences applications [2][5] - The company has approximately 1,800 global customers, primarily in the life sciences sector, including nearly every academic institution studying chemistry [3][4] Financial Performance - In the previous year, Schrödinger reported $180 million in software revenue, growing at 13% [6] - Drug discovery revenue was $27 million, down from $57 million due to a large milestone payment in 2023 [7] - Q1 revenue reached nearly $60 million, a 63% year-over-year increase, with software revenue at $48.8 million (46% growth) and drug discovery revenue at $10.7 million [8][9] - The company forecasts total software revenue growth of 10% to 15% for the year, with drug discovery revenue expected to recover to $45 million to $50 million [9] Business Model and Revenue Streams - Schrödinger's business model includes software licensing, drug discovery collaborations, and a proprietary pipeline with over eight active programs, three of which are in clinical stages [5][6] - The company benefits from cash inflows from collaborations and equity investments in co-founded companies that have gone public or been acquired [8] Strategic Priorities - The focus is on increasing adoption of computational technology among existing customers rather than acquiring new customers [12] - Enhancements to the platform will enable its use for biologics and predicting toxicology risks, aligning with FDA initiatives to phase out animal testing [12][51] Clinical Programs and Pipeline - The company is advancing three proprietary clinical programs, with data readouts expected in the second half of the year [10][20] - Preliminary efficacy data for SGR1505, a MALT1 inhibitor, shows promising results in heavily pretreated patients [14][15] Collaborations and Partnerships - Recent collaborations include a significant deal with Novartis, which involved a $150 million upfront milestone payment for drug discovery collaboration [33] - The partnership with Novartis has led to a substantial increase in software revenue, with Novartis now among the top tier of customers [36][62] Market Dynamics and Customer Insights - The company has observed no significant cutbacks in R&D spending among large pharmaceutical companies despite macroeconomic challenges [60] - Retention rates among large customers are exceptionally high at 99.9% [61] Competitive Landscape - Schrödinger differentiates itself through its unique combination of physics-based methods and machine learning, with limited direct competition in this niche [72][74] - The company views the current AI boom in drug discovery as beneficial, as it may lead to increased use of structure-based drug design, which aligns with Schrödinger's platform [73][74] Conclusion - Schrödinger is well-positioned for growth with a robust business model, strong financial performance, and strategic collaborations, while also adapting to industry trends and regulatory changes in drug discovery and development.

Investment Rating - The industry investment rating is Attractive, with a strong appeal due to growth potential in IT and software sectors [5][9]. Core Insights - IT spending for digital transformation (DX) is booming, driven by the declining working-age population in Japan, which necessitates increased IT investment as a manpower substitute [9][24]. - The report highlights several investment themes, including cloud services (SaaS/data centers), Windows 10 upgrade demand, increased defense spending, and government digitalization initiatives [10][35][39]. Summary by Sections Industry Overview - The report anticipates minimal direct impact from the increase in US tariffs on the industry [2]. - Cash flow levels at firms have risen significantly, indicating strong financial health [3]. - The working-age population decline is exacerbating labor shortages, prompting a greater focus on digitalization among management [7]. Investment Themes - Key investment themes include: - Cloud business (SaaS/data centers) [10]. - Demand for Windows 10 upgrades as support ends in October 2025 [38]. - Increased defense budget, projected to rise to approximately ¥43.5 trillion [39]. - Government initiatives for digital transformation in public administration [39]. Financial Performance - The report notes that valuations in the industry do not appear overheated, allowing for a focus on fundamentals and thematic stocks [9]. - The expected growth in IT spending is projected at a 5-year CAGR of 8% through 2028, with software investment growing at 10% and IT services at 7% [23][26]. Company Focus - Preferred stocks include: - OBIC Business Consultants (OBC), with a strong shift to cloud business and high recurring revenue [11][40]. - NTT Data, expected to see significant profit increases from its data center business [47]. - NEC, benefiting from the defense budget expansion and government digitization projects [51]. Market Trends - The report indicates that cloud spending in Japan is only 12% of total IT spending, compared to 37% globally, suggesting substantial growth potential [38]. - The overall IT spending in Japan is projected to reach ¥8,491 billion by 2025, reflecting a growth of 9.5% [33].

Financial Data and Key Metrics Changes - Total revenue for 2024 was $208 million, a decrease from $217 million in 2023 [30] - Software revenue grew by 13.3% from $159 million to $180 million, with hosted revenue increasing from $20 million to $35 million [30][34] - Q4 total revenue was $88.3 million, an increase of 19% compared to Q4 2023 [18] - Q4 software revenue was $79.7 million, up 16% from Q4 2023 [19] - The net loss for 2024 was $187 million or $2.57 per diluted share, compared to a net income of $41 million or $0.54 per diluted share in 2023 [34] Business Line Data and Key Metrics Changes - The number of software customers with an annual contract value (ACV) greater than $5 million increased from 4 to 8, while those with ACV greater than $1 million rose from 27% to 31% [12] - Total ACV increased by 24% to $191 million [12] - Drug discovery revenue for 2024 was $27 million, down from $58 million in 2023 [32] Market Data and Key Metrics Changes - Hosted revenue contributed 20% of software revenue for 2024, compared to 13% in 2023 [30] - The software gross margin for the year was 79.5%, down from 81.5% in 2023 [32] Company Strategy and Development Direction - The company aims to drive continued increases in the adoption of its computational technology and enterprise informatics platform in 2025 [13] - Plans to release several new products and solutions, including predictive toxicology technology and enhancements to biologics discovery technologies [14] - The company is optimistic about the broad momentum continuing into 2025, with expectations for software revenue growth in the range of 10% to 15% [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for a transformational 2025, with strong operational, financial, and strategic foundations [40] - The company does not expect significant growth from the Chinese market, which represents less than 5% of revenue [39] Other Important Information - The company reported a cash and marketable securities balance of $367 million at the end of Q4 2024, down from $469 million at the end of Q4 2023 [35] - The predictive toxicology project is expected to contribute significantly to revenue in 2025 [41] Q&A Session Summary Question: What is your assumption behind your 2025 drug discovery revenue guidance? - The increase in drug discovery revenue is broad-based, with contributions from various collaborations, including the Novartis partnership [57] Question: How should we think about the cadence for drug discovery revenues? - Drug discovery revenues are likely to be somewhat back-end weighted, with contributions scaling up throughout the year [125] Question: What do customers consider when moving from on-prem to hosted? - The transition to hosted contracts is seen as more seamless for delivering licenses, and the company expects a gradual increase in hosted revenue [76][78] Question: What are the stickiest aspects driving customer retention? - Customer retention is driven by the technology's impact on projects, leading to improved quality and faster development of candidates [90] Question: What is the gating factor for advancing new clinical candidates? - The company is currently evaluating potential partnerships for its clinical assets, with ongoing discussions as data becomes available [114]

Financial Performance - Total revenue for 4Q24 was $88.3 million, a 19% increase compared to $74.1 million in 4Q23[13, 23] - Software revenue for 4Q24 was $79.7 million, a 16% increase compared to $68.7 million in 4Q23[13, 23] - Drug discovery revenue for 4Q24 was $8.7 million, a 58% increase compared to $5.5 million in 4Q23[13, 23] - Total revenue for FY24 was $207.5 million, a 4.2% decrease compared to $216.7 million in FY23[13, 25] - Software revenue for FY24 was $180.4 million, a 13% increase compared to $159.1 million in FY23[13, 25] - Drug discovery revenue for FY24 was $27.1 million, a 53% decrease compared to $57.5 million in FY23[13, 25] 2025 Financial Guidance - The company expects software revenue growth of 10% - 15% in 2025[13, 43] - The company expects drug discovery revenue between $45 million and $50 million in 2025[13, 43] - The company expects operating expense growth to be less than 5% in 2025[13, 43] Key Performance Indicators - Total annual contract value (ACV) increased from $154.2 million in 2023 to $190.8 million in 2024[39] - The number of customers with ACV ≥$5M doubled from 4 in 2023 to 8 in 2024[39]